NasdaqCM:DRTSMedical Equipment
Why Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Alpha DaRT Trial Success - And What's Next
In July 2026, Alpha Tau Medical announced that its Alpha DaRT device combined with pembrolizumab produced a 100% objective response rate and a median overall survival of 18.2 months in a small clinical study of elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma, with only mild device-related side effects reported.
An interesting aspect of this trial is that it met its pre-set efficacy bar so convincingly that enrollment was stopped early for success...